0 CHECKOUT

Global Protein Therapeutics Market Outlook 2020

  • ID: 3422491
  • September 2015
  • Region: Global
  • 165 pages
  • RNCOS E-Services Private Limited
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen Inc.
  • Biogen Idec Inc.
  • Eli Lilly & Company
  • Johnson & Johnson
  • Merck Serono S.A.
  • MORE

Once a rarely used subset of medical treatments, protein therapies have now found application in a large number of medical conditions. Since the introduction of the first recombinant protein therapeutic, the human insulin, the protein therapeutics market has revolutionized tremendously. Due to its increased usage, the market holds huge potential for future growth and it is estimated that by the end of 2020, it may reach the mark of US$ 208 Billion. Furthermore, the launch of new products is also likely to propel the market growth.

According to our new research report, “Global Protein Therapeutics Market Outlook 2020”, a large number of existing and new market players are rigorously involved in developing monoclonal antibodies (mAbs). The mAbs segment accounts for the largest share in the current protein therapeutic products. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments, which includes insulin, EPO, interferon, G-CSF, human growth hormone , blood clotting factors and FSH.

The report takes into account all the important aspects of the global protein READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Amgen Inc.
  • Biogen Idec Inc.
  • Eli Lilly & Company
  • Johnson & Johnson
  • Merck Serono S.A.
  • MORE

1. Analyst View

2. Research Methodology

3. Global Protein Therapeutics Market
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2020
3.2.1 Market Segmentation
3.2.2 Market Dynamics
3.2.2.1 Drivers
3.2.2.1.1 Increasing Healthcare Expenditure in the Emerging Markets
3.2.2.1.2 Government Initiatives to Improve the Healthcare Services
3.2.2.1.3 Rising Prevalence of Chronic Diseases
3.2.2.1.4 Growing Geriatric Population
3.2.2.2 Challenges
3.2.2.2.1 High Cost of Production and Treatment
3.2.2.2.2 Competition from Biosimilars
3.2.2.2.3 Patent Expiry of Blockbuster Drugs
3.2.2.3 Opportunities
3.2.2.3.1 Potential for Bispecific Monoclonal Antibodies
3.2.2.3.2 Unmet Medical Needs in the Developing Countries

4. Industry Performance
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2020
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2020
4.2.3 By Application
4.2.4 Key Geographical Markets
4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2020
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2020
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2020
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2020
4.6.3 By Factor Type
4.6.4 Key Geographical Markets
4.6.5 Key Players and Drugs
4.6.6 Recent Developments
4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2020
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2020
4.8.3 Key Geographical Markets
4.8.4 Key Players and Drugs
4.8.5 Recent Developments

5. Advanced Phase Drugs Analysis

6. Emerging Market Trends
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
6.4 Increasing Focus on Development of Biobetters

7. Porters Five Forces Analysis

8. Key Players
8.1 Johnson & Johnson
8.2 Biogen Idec Inc.
8.3 Eli Lilly & Company
8.4 Sanofi-Aventis
8.5 Merck Serono S.A.
8.6 Roche Group
8.7 Amgen Inc.
8.8 Pfizer
8.9 Abbott Laboratories
8.10 Novo Nordisk

List of Tables
Table 3-1: US & Europe - Major Drugs Patent Expiry in Protein Therapeutics Market
Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2012-2014
Table 4-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2012-2014
Table 4-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2012-2014
Table 4-4: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2012-2014
Table 4-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
Table 4-6: Europe - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-7: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
Table 4-8: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2012-2014
Table 4-9: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2012-2014
Table 4-10: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2012-2014
Table 4-11: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2012-2014
Table 4-12: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2012-2014
Table 4-13: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2014
Table 5-1: Advanced Phase Protein Therapeutics
Table 8-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 8-2: Biogen - Key Products in Protein Therapeutics
Table 8-3: Eli Lilly - Key Products in Protein Therapeutics
Table 8-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 8-5: Merck Serono - Key Products in Protein Therapeutics
Table 8-6: Roche - Key Products in Protein Therapeutics
Table 8-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 8-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 8-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 8-10: Novo Nordisk - Key Products in Protein Therapeutics

List of Figures
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2013-2020
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2014
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2020
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2014
Figure 4-3: Global - Monoclonal Antibodies Application in Cancer Treatment (Billion US$), 2013-2020
Figure 4-4: Global - Monoclonal Antibodies Application in Rheumatoid Arthritis Treatment (Billion US$), 2013-2020
Figure 4-5: Global - Monoclonal Antibodies Application in Other Chronic Diseases Treatment (Billion US$), 2013-2020
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-9: Global - Monoclonal Antibody Market by Key Players (%) (2014)
Figure 4-10: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-11: Global - Erythropoietin Market by Segment (%) (2014)
Figure 4-12: Global - Number of Patients on Dialysis (Million), 2014 & 2020
Figure 4-13: Global - Breakup of Patients on Dialysis by Region (%), 2014
Figure 4-14: Global - Number of New Cancer Cases (Million), 2012 & 2020
Figure 4-15: Global - Breakup of New Cancer Cases by Region (%), 2020
Figure 4-16: US - Erythropoietin Market (Billion US$), 2013-2020
Figure 4-17: Europe - Erythropoietin Market (Billion US$), 2013-2020
Figure 4-18: Global - Erythropoietin Market by Key Player (%), (2014)
Figure 4-19: Global - Insulin Market (Billion US$), 2013-2020
Figure 4-20: Global - Number of Diabetic Patients (Million), 2013 & 2035
Figure 4-21: US - Insulin Market (Billion US$), 2013-2020
Figure 4-22: Europe - Insulin Market (Billion US$), 2013-2020
Figure 4-23: Asia - Insulin Market (Billion US$), 2013-2020
Figure 4-24: Global - Insulin Market by Key Players (%) (2014)
Figure 4-25: Global - Insulin Market by Products (%)(2014)
Figure 4-26: Global - Interferon Market (Billion US$), 2013-2020
Figure 4-27: Global - Interferon Market by Segment (%) (2014)
Figure 4-28: Global - Interferon Alpha Market (Billion US$), 2012-2014
Figure 4-29: Global - Interferon Beta Market (Billion US$), 2012-2014
Figure 4-30: US - Interferon Market (Billion US$), 2013-2020
Figure 4-31: Europe - Interferon Market (Billion US$), 2013-2020
Figure 4-32: Global - Interferon Market by Key Player (%) (2014)
Figure 4-33: Global - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-34: US - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-35: Europe - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-36: Global - Human Growth Hormone Market by Key Players (%) (2014)
Figure 4-37: Global - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-38: Global - Blood Clotting Factor Market by Segment (%) (2014)
Figure 4-39: Global - Blood Clotting Recombinant Factor VIII Market (Billion US$), 2013-2020
Figure 4-40: Global - Recombinant Blood Clotting Factor VII Market (Billion US$), 2013-2020
Figure 4-41: Global - Recombinant Blood Clotting Factor Market IX (Billion US$), 2013-2020
Figure 4-42: US - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-43: Europe - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-44: Global - Blood Clotting Factor Market by Key Players (%) (2014)
Figure 4-45: Global - Follicle Stimulating Hormone Market (Billion US$), 2013-2020
Figure 4-46: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2013-2020
Figure 4-47: US - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
Figure 4-48: Europe - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
Figure 7-1: Porters Five Forces Analysis

Note: Product cover images may vary from those shown
3 of 4

- Abbott Laboratories
- Amgen Inc.
- Biogen Idec Inc.
- Eli Lilly & Company
- Johnson & Johnson
- Merck Serono S.A.
- Novo Nordisk
- Pfizer
- Roche Group
- Sanofi-Aventis

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • AbbVie, Inc.
  • Hospira
  • Biocon
  • Celltrion
  • Bayer AG
  • Baxter International Inc.